CureVac Shareholders Face Pivotal Acquisition Vote

A defining moment approaches for investors in CureVac as the biotechnology firm prepares for a crucial shareholder vote on November 25. This landmark decision will determine whether competitor BioNTech proceeds with a complete acquisition of the company, though the arrangement remains contingent upon meeting specific approval thresholds.

Under the proposed acquisition terms, BioNTech has presented an offer valuing CureVac at approximately $1.25 billion. The arrangement provides CureVac shareholders with $5.46 per share, though notably this compensation would come not as cash but through BioNTech stock. A specialized protective mechanism has been incorporated into the deal to shield shareholders from potential stock price volatility, though this feature adds considerable complexity to the transaction.

Significant Approval Hurdle Presents Challenge

The acquisition faces its most substantial obstacle in the form of approval requirements. BioNTech has stipulated that between 75% and 80% of CureVac shareholders must endorse the deal for it to proceed. This exceptionally high threshold creates substantial uncertainty, transforming the outcome into a suspenseful situation that may remain undecided until the final moments of voting. Should the required majority fail to materialize, the entire arrangement could collapse, potentially triggering significant volatility in CureVac's share price.

Should investors sell immediately? Or is it worth buying CureVac?

Market Sentiment Reflects Optimism

Recent market activity suggests investors are increasingly confident about the acquisition's prospects. CureVac shares have demonstrated remarkable strength, climbing more than 90% over the past twelve months and gradually approaching the valuation implied by BioNTech's offer. This positive momentum follows August's patent dispute resolution with Pfizer and BioNTech, which delivered a substantial $740 million windfall to CureVac and its development partner GSK.

The ultimate decision now rests with CureVac's shareholders: will they embrace the acquisition offer or elect to maintain the company's independent trajectory? The answer will emerge within days, potentially reshaping CureVac's market valuation for the foreseeable future.